Gmail - Semafore Granted Nearly One Million Dollars to Study SF1126 in Multiple Myeloma Patients
Â Semafore Pharmaceuticals, Inc. today announced receipt of a grant award from the Multiple Myeloma Research Foundation (MMRF) for a Phase l trial evaluating its Pl3K inhibitor SF1126 in multiple myeloma.
This is the second clinical trial grant awarded to Semafore-last week the company announced receipt of a grant from Cancer Treatment Research Foundation (CTRF) to help fund a Phase l trial of SF1126 in solid cancers.
Both Phase l trials are expected to commence in 2007. Separately, Semafore announced that multiple myeloma preclinical studies sponsored by the company and its collaborators at Emory University have been selected for an oral presentation at the upcoming 48th Annual Meeting of the American Society of Hematology (ASH.) "This generous grant from the MMRF will enable us to rapidly initiate a clinical trial of SF1126 in multiple myeloma," said Dr. Joseph Garlich, president and chief scientist of Semafore. "The MMRF has an outstanding track record of funding innovative research that has significantly increased the treatment options available to myeloma patients.
The PI3 kinase pathway plays a key role in the signaling processes that are vital to cancer cell proliferation, invasion and metastasistermterm, yet there currently are no PI3K inhibitors in clinical trials. We are therefore delighted that both the MMRF and the CTRF have chosen to support cancer trials of our lead Pl3K inhibitor scheduled to begin in the new year." The MMRF has awarded Semafore a $996,380 grant to help fund both the drug manufacturing and the patient costs of a Phase l trial in relapsed and refractory multiple myeloma patients. The grant award is from the new MMRF LEAD program designed to encourage myeloma clinical trials for promising new drugs being developed by young companies.
MMRF founder and chief executive officer Kathy Giusti noted, "Our mission is to accelerate the development of promising new drugs for myeloma, and Semafore's innovative approach that targets the Pl3 kinase pathway has shown significant promise in preclinical studies. There currently are no Pl3K inhibitors in clinical trials, so it is fitting that this promising new approach is one of the first recipients of our new LEAD clinical awards program." The MMRF's LEAD program is a multi-year research grant commitment intended to drive and accelerate the development of innovative and effective multiple myeloma treatments by funding the development of lead compounds through the early stage drug development process that could have a significant impact on existing or future myeloma treatments. Dr Garlich concluded, "The growing interest in the anti-cancer potential of our Pl3K approach is also highlighted by the fact that data from preclinical studies of SF1126 in myeloma were selected for an oral presentation at the upcoming ASH meeting, a noteworthy occurrence for a preclinical study." SF1126 Oral Presentation at ASH: "A vascular targeted pan PI-3 kinase inhibitor, SF1126, with activity against multiple myeloma in vivo"* At the 48th Annual Meeting of the American Society for Hematology in Orlando, Florida, Dr. Donald L. Durden** will give an oral presentation of in vitro and in vivo preclinical data on SF1126 in multiple myeloma. Semafore has collaborated with Emory University to conduct these studies, with the financial support of the Multiple Myeloma Research Consortium (MMRC). The presentation is abstract # 244 scheduled for December 11, 2006 at 8:15 am EST in Chapin Theater (Level III). * Authors of the study include Pradip De, Qiong Peng, Nandini Dey, Breanne McDermitt, Sagar Lonial and Donald L. Durden from Emory University, and Xiaodong Peng and Joseph Garlich from Semafore Pharmaceuticals. ** Professor of pediatric oncology and hematology at Emory University School of Medicine, scientific director of basic and translational research at the AFLAC Institute for Cancer and Blood Disorders, and chairman of Semafore's Scientific Advisory Board.